Colombia vs Mexico: HIV/AIDS deaths averted by antiretroviral therapy
Colombia
11,670 deaths
in 2023
Mexico
12,379 deaths
in 2024
Colombia rank
21st
Mexico rank
19th
HIV/AIDS deaths averted by antiretroviral therapy over time
- Colombia
- Mexico
How they compare
Mexico currently reports 12,379 deaths against 11,670 deaths in Colombia, a difference of 709 deaths.
That makes Mexico's figure about 1.1 times Colombia's.
Across all 34 years both countries report, Mexico has been ahead every year.
Colombia ranks 21st and Mexico ranks 19th of 157 countries.
Mexico has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Colombia | Mexico | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 0 deaths | 379.05 deaths | 379.05 deaths | Mexico |
| 2000s | 1,534 deaths | 3,660 deaths | 2,126 deaths | Mexico |
| 2010s | 6,492 deaths | 8,109 deaths | 1,617 deaths | Mexico |
| 2020s | 10,904 deaths | 11,463 deaths | 558.23 deaths | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hiv/aids deaths averted by antiretroviral therapy, Colombia or Mexico?
- Mexico, at 12,379 deaths against 11,670 deaths in Colombia as of 2024.
- What is the difference in hiv/aids deaths averted by antiretroviral therapy between Colombia and Mexico?
- 709 deaths, with Mexico ahead.
- How many years of comparable data are there for Colombia and Mexico?
- 34 years are reported by both, from 1990 to 2023.
- How do Colombia and Mexico rank globally for hiv/aids deaths averted by antiretroviral therapy?
- Colombia ranks 21st and Mexico ranks 19th of 157 countries.
- Where does this data come from?
- Joint United Nations Programme on HIV/AIDS (2026) – with minor processing by Our World in Data, published as HIV/AIDS deaths averted by antiretroviral therapy. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of deaths prevented as a direct result of Antiretroviral Therapy (ART) among people living with HIV. It is calculated by comparing the observed mortality rates in individuals receiving ART to the estimated mortality rates in the absence of such treatment. This is the central estimate.